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Fergus Hamilton, David Arnold and Rupert Payne
Association of prior lymphopenia with mortality 
in pneumonia:
a cohort study in UK primary care
INTRODUCTION
Lymphopenia (a reduction in the normal 
concentration of lymphocytes) has long 
been implicated as a potential biomarker 
for acute infection; many studies show 
that lymphopenia during, or at the start 
of, infection is associated with poor 
outcomes.1–4
Exploring the mechanisms and 
therapeutic implications of this 
phenomenon has been the subject of recent 
reviews, and remains largely unexplained.5,6
Recent work has also shown that 
lymphopenia may predict infection, and 
infection-related mortality, even when 
the lymphocyte count test significantly 
precedes the infection, with some studies 
supporting an increased risk of a wide 
range of infections (including pneumonia) 
and infection-related mortality, though no 
work has been performed in the broader 
primary care population with pneumonia.7,8 
Respiratory infections such as pneumonia 
are very common in primary care,9 and 
greater understanding of predictive features 
would be of significant value to clinicians.
In this study the effect of lymphocyte 
counts on mortality was estimated in a 
large, unselected, primary care population 
with primary-care coded pneumonia.
METHOD
This cohort study was performed in the 
Clinical Practice Research Datalink (CPRD), 
a large, representative UK primary care 
database, which holds coded primary care 
electronic health records, including blood 
tests, prescriptions, diagnostic codes, and 
immunisations. Of the English practices in 
this database, 70% are linked to the Office 
for National Statistics (ONS) mortality data; 
a national death registry. 
Analysis was conducted and reported 
in line with the STROBE guidance (see 
Supplementary Box S1). 
Participants
Participants in this study were included from 
January 1998 until January 2019, had a 
coded diagnosis of pneumonia, and were 
aged >50 years at the time of pneumonia 
diagnosis. No other clinical exclusion criteria 
were used. CPRD records were included if 
they were considered ‘up to standard’ and 
of ‘acceptable’ quality (both internal CPRD 
metrics) for 6 months before a pneumonia 
diagnosis. If participants had multiple 
pneumonia episodes, the first episode was 
the one used.
Outcomes
The primary outcome in this study was 
28-day mortality, with a secondary outcome 
of 1-year mortality following pneumonia 
diagnosis.
Lymphopenia definition
Blood test data are automatically extracted 
from GP medical records into the CPRD, 
with tests performed on a variety of 
Abstract
Background
Lymphopenia (reduced lymphocyte count) during 
infections, such as pneumonia, is common and is 
associated with increased mortality. Little is known 
about the relationship between lymphocyte count 
before developing infections and mortality risk.
Aim
To identify whether patients with lymphopenia who 
develop pneumonia have increased risk of death.
Design and setting
A cohort study set in the Clinical Practice 
Research Datalink (CPRD) linked to national 
death records, in primary care. This database 
is representative of the UK population and is 
extracted from routine records.
Method
Patients aged >50 years with a pneumonia 
diagnosis were included from January 1998 
until January 2019. The relationship between 
lymphocyte count and mortality was measured, 
using a time-to-event (multivariable Cox 
regression) approach, adjusted for age, sex, social 
factors, and potential causes of lymphopenia. The 
primary analysis used the most recent test before 
pneumonia. The primary outcome was 28-day, 
all-cause mortality. 
Results
A total of 40 909 participants with pneumonia 
were included, with 28 556 having had a 
lymphocyte count test before pneumonia (median 
time between test and diagnosis was 677 days). 
When lymphocyte count was categorised 
(0–1 × 109 cells/L, 1–2 × 109 cells/L, 2–3 × 109 
cells/L, >3 × 109 cells/L, never tested), both 
28-day and 1-year mortality varied significantly: 
14%, 9.2%, 6.5%, 6.1%, and 25%, respectively, 
for 28-day mortality, and 41%, 29%, 22%, 20%, 
and 52% for 1-year mortality. In multivariable 
Cox regression, lower lymphocyte count was 
consistently associated with increased hazard of 
death. 
Conclusion
Lymphopenia is an independent predictor of 
mortality in primary care pneumonia. Even 
low–normal lymphopenia (1–2 × 109 cells/L) is 
associated with an increase in short- and long-
term mortality compared with higher counts. 
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platforms, across multiple laboratories in 
the UK. All laboratory results are used for 
routine clinical work, and there is likely to be 
limited relevant laboratory variation for this 
assay. The result and date of the test were 
extracted, and extreme values (lymphocyte 
count >10 × 109 cells/L) were removed as 
outliers. 
As most patients had multiple lymphocyte 
tests, several strategies were considered to 
define lymphocyte count for the subsequent 
analysis. The primary analysis was simply 
the most recent count, with no restrictions 
on time from blood test until pneumonia. 
The authors arbitrarily categorised this 
into integer cut points (0–1 × 109 cells/L, 
1–2 × 109 cells/L, 2–3 × 109 cells/L, 
and >3 × 109 cells/L) for ease of clinical 
interpretation in primary analysis.
Multiple other approaches for quantifying 
lymphocyte count were performed, with 
details in the sensitivity analysis shown 
later.
Confounding variables
As lymphocyte counts and mortality from 
pneumonia are known to be related to 
many common patient-level factors, 
relevant confounders were extracted from 
the CPRD. These included specific medical 
comorbidities, smoking status, alcohol 
usage, corticosteroid use, age (at time 
of pneumonia diagnosis), sex, and area-
based socioeconomic deprivation (index of 
multiple deprivation [IMD]).
Medical comorbidities that are known 
to impact on lymphocyte count or 
mortality from pneumonia were included: 
cancer, autoimmune disease, organ 
transplantation, stem cell transplantation, 
HIV disease, previous stroke, diabetes (any 
type), peripheral vascular disease, and 
previous myocardial infarction. 
All comorbidities, except cancer, were 
defined based on any relevant diagnostic 
code recorded before having pneumonia. 
Any cancer code (excluding non-melanotic 
skin cancer) in the preceding 2 years was 
taken as evidence of cancer. 
Smoking status was categorised into 
‘never smoker’, ‘current smoker’, or 
‘ex-smoker’ based on clinical codes, and 
alcohol use defined by the presence of a 
variety of diagnostic codes for increased 
alcohol consumption. In patients without 
any smoking-related codes, smoking status 
was coded as ‘unknown’.
Corticosteroid use was defined as 
the prescription of >2 issues of an oral 
corticosteroid over the last 12 months, 
irrespective of dose or duration of issue. 
Finally, calendar year was included as a 
continuous variable, as management of 
pneumonia and testing may have changed 
over the period of the study.
Statistical approach
Initially, patients who had ever had 
lymphocyte testing were compared with 
those who had never been tested, to identify 
any biases related to testing within the 
dataset. 
Subsequently, primary analysis was by 
Cox regression to calculate hazard ratios 
(HRs), adjusted for the aforementioned 
covariates. Both non-adjusted and adjusted 
Kaplan–Meier curves were generated, 
with the adjusted plots generated with the 
How this fits in 
Low lymphocyte levels during infection are 
common and associated with increased 
risk of death. This study, in a representative 
UK primary care population, shows that 
having a low lymphocyte count before 
acquiring an infection — even years before 
— is also associated with an increased risk 
of dying. 
Table 1. Participant demographics, N = 40 909
  Never tested, n, %a Tested, n, %a  
Characteristic (n = 5219) (n = 35 690) P-valueb
Age, years, median (IQR)  81 (69–88) 76 (66–85) <0.001
Sex, female 2740 (52.5) 18 020 (50.5) 0.007
Comorbidities
 Diabetes 421 (8.1) 5404 (15.1) <0.001
 HIV status 2 (<0.1) 22 (0.1) 0.8
 Ischaemic heart disease 829 (15.9) 7093 (19.9) <0.001
 Ischaemic stroke 1030 (19.7) 5337 (15.0) <0.001
 Alcohol excess 98 (1.9) 834 (2.3) 0.043
 Autoimmunity 505 (9.7) 6054 (17.0) <0.001
 Corticosteroid user 467 (8.9) 5134 (14.4) <0.001
 Peripheral vascular disease 227 (4.3) 1844 (5.2) 0.013
 Stem cell transplant 3 (0.1) 17 (<0.1) 0.7
 Solid organ transplant 9 (0.2) 130 (0.4) 0.036
 Cancer (solid organ) 224 (4.3) 1692 (4.7) 0.2
 Haematological cancer 36 (0.7) 393 (1.1) 0.008
Smoking status     <0.001
 Never smoker 1594 (30.5) 8021 (22.5) —
 Ex-smoker 920 (17.6) 16 165 (45.3) —
 Current smoker 467 (8.9) 3368 (9.4) —
 Unknown 2238 (42.9) 8136 (22.8) —
Mortality
 28 day 1318 (25.3) 2601 (7.3) <0.001
 1 year 2721 (52.1) 8377 (23.5) <0.001
aUnless stated otherwise. bStatistical tests performed: Wilcoxon rank-sum test; c2 test of independence; Fisher’s 
exact test. IQR = interquartile range.
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marginal approach allowing for differential 
weighting of subgroups.10
Lymphocyte count was treated as a 
categorical variable (cut at integer break 
points for ease of clinical interpretation). 
Only patients with a recorded result 
were included in the primary analysis. 
Age was modelled as a linear variable. 
Smoking status and IMD were modelled as 
categorical variables. All other covariates 
were treated as binary. Very rare variables 
(<50 occurrences) were removed. As a 
secondary analysis, and for the purposes of 
visualisation, a restricted cubic spline Cox 
model was generated using lymphocyte 
count as a continuous variable.
As ‘up-to-standard’ CPRD data are 
relatively complete, and diagnosis was 
defined by the presence of a code, missing 
data were relatively rare. As such, a 
complete case analysis was performed. 
Follow-up was censored at 1 year. All 
analysis was performed in R (version 3.6.1), 
using the packages ‘tidyverse’, ‘survival’, 
‘broom’, ‘Hmisc’, and ‘survminer’, with 
table generation using ‘tidyverse’ and 
‘gtsummary’.10,11
Sensitivity analyses
As many patients had multiple tests, 
multiple alternative approaches were 
explored to define lymphocyte count, 
categorising lymphocyte count based on 
quartiles rather than integer cut points, 
and additionally using alternative choice 
of measurements, that is, excluding 
measurements >1 year before pneumonia 
diagnosis; excluding measurements 
<6 months before pneumonia diagnosis; 
using the first ever measurement; and 
selecting the maximum, minimum, and 
mean counts irrespective of time.
In order to consider the potential bias 
generated by testing, a subsequent Cox 
model including patients who had never 
had a lymphocyte count before pneumonia 
was generated.
Finally, length of time between the most 
recent test and pneumonia (time-to-event 
approach) was included as an interaction 
term with lymphocyte count.
Data sharing
The Medicines and Healthcare products 
Regulatory Agency do not allow sharing 
of raw CPRD data. If access is required, 
Independent Scientific Advisory Committee 




A total of 40 909 participants were included 
in this study. Participant demographics 
are shown in Table 1, comparing patients 
who had ever had a lymphocyte count test 
Table 2. Crude mortality for integer lymphocyte count cut off 
 Lymphocyte count × 109 cells/L, n (%)
Outcomes 0–1 (n = 3931) 1–2 (n = 14 963) 2–3 (n = 7419) >3 (n = 2243)
Primary:  
28-day mortality  548 (13.9) 1375 (9.2) 485 (6.5) 136 (6.1)
Secondary:  
1-year mortality 1606 (40.9) 4273 (28.6) 1627 (21.9) 456 (20.3)
Figure 1. Distribution of lymphocyte counts across all 
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(n = 35 690) with participants never tested 
(n = 5219). 
Participants who had no blood tests 
recorded were generally slightly older than 
other participants, but with lower rates 
of all comorbidities. Remarkably, patients 
who had never had a lymphocyte test had 
a significant 1-year mortality of 52.1%, 
suggesting the tested group is significantly 
different to the non-tested one.
Lymphocyte test timings and distributions
Across the 35 690 patients tested, 368 870 
tests were performed. Patients had a 
median of 7 (interquartile range [IQR] 3–13) 
tests and the distribution of tests was highly 
skewed to the left. The maximum number 
of tests on one person was 287, though the 
vast majority of patients had far fewer. 
Testing steadily increased before 
diagnosis, with the peak number of 
tests just before pneumonia diagnosis 
(see Supplementary Figure S1). This 
was also highly skewed, with a median 
time from test of 677 days (IQR 10–1720). 
Lymphocyte test results were essentially 
normally distributed, with a mean (standard 
deviation [SD]) of 1.85 (0.88) × 109 cells/L, as 
demonstrated in Figure 1.
There was no clear relationship between 
numbers of tests and lymphocyte count 
(see Supplementary Figure S2).
Relationship between lymphocyte count 
and mortality
For the main analysis, the most recent 
lymphocyte count before pneumonia was 
chosen. This limited the sample size to 
28 556 patients, as 7124 participants only 
had lymphocyte counts measured after, or 
on, the date of pneumonia diagnosis and 
were excluded. Of those 28 556 patients, 
2544 (8.9%) met the primary outcome (died 
within 28 days), and 7962 (27.9%) met the 
secondary outcome (died within 1 year) 
(Table 2). 
There was a clear relationship between 
lymphocyte count and both outcomes. 
Figure 2 shows the relationship from the 
restricted cubic spline model, showing a 
non-linear increase in risk of mortality with 
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Figure 2. Restricted cubic spline model showing 
relationship between lymphocyte count and mortality 
at (a) 28 days and (b) 1 year.  
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Crude mortality figures for each integer 
cut off are presented in Table 2, which show 
a clear decrease in risk with increasing 
lymphocyte count. 
Cox regression
Multivariable Cox regression was 
undertaken, with mortality censored at 
either 28 days (primary outcome) or 1 year 
(secondary outcome) (see Table 3). Due to 
low numbers of cases, HIV status and stem 
cell transplantation were removed from the 
Cox model.
There was a clear association between 
having low lymphocyte count and 
increased risk of death at 28-days post-
pneumonia, with an adjusted HR of 1.63 
(95% confidence interval [CI] = 1.44 to 1.84) 
for lymphocyte counts <1 × 109 cells/L 
compared to 2–3 × 109 cells/L. A similar 
effect was observed for 1-year mortality 
(adjusted HR 1.59, 95% CI = 1.48 to 1.71). 
Unsurprisingly, most comorbidities were 
also associated with increased mortality, 
except autoimmunity and ischaemic heart 
disease, which were both associated with 
reduced mortality at 28 days and 1 year. 
Corresponding Kaplan-Meier survival 
curves are shown in Figure 3 (adjusted) and 
Supplementary Figure S3 (unadjusted).
Sensitivity analyses
For the quartile model, full Cox regression 
outputs for the primary outcome are 
shown in Supplementary Table S1. Briefly, 
there remained a strong relationship with 
mortality, with the HR for death for those in 
the lowest quartile (0.09–1.31 x 109 cells/L) 
of 1.56, 95% CI = 1.39 to 1.74. Mortality at 
28 days was 13.9% and 6.1% in the lowest 
and highest quartiles of lymphocyte count, 
respectively (see Supplementary Table S2).
Abbreviated results (HR for lymphocyte 
count only) of models using alternative 
exposure definitions are presented 
in Supplementary Table S3. These 
associations were also maintained 
when the timing of testing was varied; 
the strongest association between 
lymphopenia and mortality was observed 
when only measurements in the past year 
were included (HR 1.57, 95% CI = 1.45 to 
1.69 for lowest versus highest quartile 
of lymphocyte count), and the weakest 
association was observed when either the 
first measurement or mean measurement 
was used (HR 1.29, 95% CI = 1.21 to 1.37 
Table 3. Adjusted Cox regression outputs for 28-day and 1-year mortality
 28-day mortality 1-year mortality
Characteristica HR 95% CI P-value HR 95% CI P-value
Age, years 1.06 1.06 to 1.07 <0.001 1.06 1.05 to 1.06 <0.001
Sex, female 1.00 0.93 to 1.09 >0.90 0.87 0.83 to 0.91 <0.001
Lymphocyte count, × 109 cells/L      
 0–1 1.63 1.44 to 1.84 <0.001 1.59 1.48 to 1.71 <0.001
 2–3  ref ref — ref ref —
 1–2 1.15 1.03 to 1.27 0.009 1.14 1.08 to 1.21 <0.001
 >3 0.95 0.78 to 1.15 0.6 0.91 0.82 to 1.01 0.069
Comorbidities      
 Diabetes 0.99 0.89 to 1.11 0.90 1.07 1.01 to 1.14 0.027
 Ischaemic heart disease 0.82 0.74 to 0.90 <0.001 0.98 0.93 to 1.03 0.40
 Ischaemic stroke 1.40 1.28 to 1.54 <0.001 1.29 1.22 to 1.36 <0.001
 Peripheral vascular disease 0.95 0.81 to 1.13 0.60 1.08 0.99 to 1.18 0.081
 Alcohol excess 1.52 1.15 to 2.02 0.004 1.32 1.13 to 1.55 <0.001
 Autoimmunity 0.87 0.77 to 0.97 0.010 0.92 0.87 to 0.98 0.005
 Solid organ transplant 0.97 0.40 to 2.33 >0.90 1.14 0.76 to 1.70 0.50
 Cancer (solid organ) 2.86 2.52 to 3.23 <0.001 2.98 2.77 to 3.20 <0.001
 Haematological cancer 0.95 0.64 to 1.41 0.80 1.73 1.46 to 2.06 <0.001
 Corticosteroid user 1.12 1.00 to 1.26 0.053 1.36 1.28 to 1.44 <0.001
Smoking status      
 Never smoker ref ref — ref ref —
 Ex-smoker 0.97 0.87 to 1.08 0.50 1.05 0.99 to 1.12 0.12 
 Current smoker 1.42 1.20 to 1.67 <0.001 1.48 1.35 to 1.62  <0.001
 Unknown 1.43 1.28 to 1.60 <0.001 1.25 1.17 to 1.34 <0.001
Calendar year 0.95 0.94 to 0.96 <0.001 0.97 0.96 to 0.97 <0.001
aHIV status and stem cell transplant removed as few instances; Index of Multiple Deprivation not shown for brevity. HR = hazard ratio. 
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for first measurement). The association 
was maintained (HR 1.37, 95% CI = 1.28 to 
1.47) when measurements in the 6 months 
before pneumonia were excluded to ensure 
results were not directly related to the 
pneumonia itself.
Finally, the association persisted when the 
minimum, maximum, or mean lymphocyte 
count was used; the minimum count 
showed a stronger association (HR 1.59, 
95% CI = 1.49 to 1.70). Unsurprisingly, 
the time between lymphocyte test and 
pneumonia varied significantly with each 
definition. In the ‘first ever’ approach, the 
median time from test until pneumonia was 
1720 days (data not shown).
In summary, the association between 
alternative definitions of lymphocyte count 
and outcomes was maintained; however, 
the association was strongest when 
using lymphocyte tests that were closely 
temporally related to the pneumonia 
diagnosis, and when taking the minimum 
ever recorded lymphocyte count.
In the sensitivity analysis including 
patients who had never had a lymphocyte 
test (n = 5219) risk estimates were similar, 
with an HR of 1.66, 95% CI = 1.47 to 1.88 
for a lymphocyte count of 0–1 x109 cells/L 
compared to the reference (2–3 x 109 cells/L) 
(see Supplementary Table S4).
There was no evidence from the 
interaction model that the strength of 
association between lymphocyte count and 




In this large primary care cohort of 
patients with pneumonia, there was a 
clear relationship between low lymphocyte 
count and increased mortality. In particular, 
even mild lymphopenia, within the defined 
normal range (lymphocyte count 1–2 × 109 
cells/L), was associated with a significant 
increase in both short- and longer-term 
mortality. 
Lymphopenia is robustly associated 
with short- and long-term survival in 
pneumonia, with increasing risk with 
lower lymphocyte counts. Patients with 
low–normal lymphocyte counts (1–2 x 109 
cells/L) are at significantly increased risk 
of mortality.
Strengths and limitations
This study has many strengths. First, 
the large-scale cohort used a nationally 
representative UK primary care dataset, 
linked to mortality data. Second, the large 
number of study patients (N = 28 556) 
allowed for firm conclusions about risk 
Figure 3. Kaplan-Meier curves for survival from 
pneumonia at 1 year, stratified by lymphocyte count 
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estimates, and the quality of CPRD coding 
enabled testing for multiple covariates, 
none of which substantially altered the 
hazard estimate. Third, the wide variety of 
approaches to defining lymphocyte count 
provided reassurance that this is not simply 
a testing phenomenon.12 In particular, even 
definitions using relatively historic results 
(for example, first ever lymphocyte count) 
showed an association with subsequent 
pneumonia mortality. 
This study has weaknesses consistent 
with similar observational analyses of large 
routine datasets. In particular, the authors 
did not have information on why tests were 
performed, though an interaction between 
number of tests and the outcome was not 
found. It is also important to note that around 
15% of patients did not have a recorded test, 
and this population was quite different to 
the tested population, with a 52.1% 1-year 
mortality. Second, though a broad range of 
confounding variables were included, it is 
possible that other causes for lymphopenia 
were not recorded, for example, moderate 
alcohol intake not reported to GP. Despite 
this, unadjusted and adjusted risk estimates 
were broadly similar. Third, the present 
cohort comprised patients aged >50 years 
at the time of pneumonia diagnosis, and 
it is therefore necessary to be cautious 
about extrapolating findings to younger 
individuals. 
Comparisons with existing literature
There has been significant research interest 
in lymphopenia as a marker of poor immune 
function, though much work is pre-clinical 
and focuses on potential mechanisms of 
immune dysfunction.5 It remains unclear 
whether lymphopenia represents chronic 
failure of the immune system, or simply 
dysregulation. Some studies have found 
significant apoptosis of lymphocytes 
after infection, and this perhaps reflects 
dysregulation of immune control, rather 
than failure to maintain lymphocyte 
counts.5,13 It is also well established that 
lymphopenia occurs in critical illness, and it 
may be that lymphopenia simply represents 
an epiphenomena of sickness, though 
adjustment for other markers of sickness 
in the present study was made.7
In clinical data, one Oxford-based cohort 
study of adult emergency admissions 
showed lymphopenia to be an independent 
predictor of bacteraemia, though with 
modest performance (area under the curve 
0.63).1 In a large, Danish population study 
of 98 344 invited individuals in Copenhagen, 
lymphopenia (defined as <1.1 × 109 cells/L) 
was associated with a significant increase 
in infection and infection-related death 
(adjusted HR 1.41, 95% CI = 1.28 to 1.56 
for any infection; HR 1.70, 95% CI = 1.37 to 
2.10 for infection-related death).8 Of note, 
only 2352 (approximately 3%) of individuals 
had lymphopenia at this examination by 
their definition, and this was an invited 
population study, hence mortality was 
much reduced compared with the present 
study (5636 deaths [5.7%] at median follow 
up of 6 years). Of note, in contrast to the 
present study, increased mortality was not 
associated with low–normal lymphopenia 
(1–2 × 109 cells/L). Another recent US study 
on a large invited cohort of 31 178 (the 
National Health and Nutrition Examination 
Survey) individuals found a relationship 
between lymphopenia and mortality, 
with a multivariable adjusted HR of 1.8, 
95% CI = 1.6 to 2.1 for all-cause mortality 
with severe lymphopenia (lymphocyte 
count <1 × 109 cells/L).14 Of note, this also 
relied on a single measure, and only half of 
patients included had linked mortality data, 
raising concern for bias. 
Other work has focused on lymphopenia 
after diagnosis in infection as a poor 
prognostic marker,2,3,15 with one study 
on pneumonia (participants, N = 3043) 
finding lymphopenia as a predictor of 
early but not late mortality, in contrast to 
the present findings.3 In another study,15 
severe lymphopenia (<0.724 x 109 cells/L) 
was tested as an addition to CURB-65, a 
prognostic tool for pneumonia,16 modestly 
improving the predictive performance 
(C-statistic increased from 0.722 to 0.739) in 
a validation cohort. 
In both studies set in secondary care, 
lymphopenia may represent acute illness, 
in contrast to the present study’s setting in 
primary care, where lymphopenia is more 
likely to be chronic.4
As far as the authors are aware, no 
studies have been performed in primary 
care looking at lymphopenia with a focus 
on pneumonia, which has significant 
implications. The vast majority of patients 
with respiratory tract infection present 
to primary care, and risk stratification 
here is critical. Further, the potential for 
identification and potential therapeutics 
is greater than in secondary care, as 
discussed in the next section.
Implications for research and practice
This present study suggests lymphopenia is 
associated with both short- and long-term 
mortality. This has implications for risk 
stratification and for future therapeutics. 
For risk stratification, the authors suggest 
that even low–normal lymphopenia 
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should be considered as a part of triage in 
identifying those likely to die. Further studies 
should evaluate this with other markers 
and scores for predicting outcomes in 
pneumonia, such as CURB-65. Alongside 
this, the role of lymphopenia in predicting 
occurrence and outcome of infection should 
be studied. Finally, the dramatic 1-year 
mortality (52.1%) in the non-tested group 
provides further evidence that indications 
for testing can strongly alter the predictive 
value of testing; that is a clinician decision 
to perform a test in itself can be predictive 
of mortality, thereby altering the predictive 
ability of that test; and clinicians should 
take this into account when interpreting 
this study.
For therapeutics, researchers should 
focus on identifying whether this is 
an epiphenomenon, or represents an 
opportunity to intervene in a dysregulated 
immune system. In particular, more 
accurate characterisation of lymphocyte 
functionality in pneumonia would be of 
significant value in assessing whether this 
is a therapeutic target.
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